Get started
Author

Muhammad Hafi Abid

Observed name: Muhammad Ali Abid
ORCID: 0009-0001-9191-3619
Observed ORCIDs: 0009-0001-9191-3619, 0009-0001-9623-042X
OpenAlex ID: A5135069157
Sublingual Cyclobenzaprine Approval: Expanding Options for Fibromyalgia Management
2026 · Muhammad Ali Abid, Muhammad Hafi Abid, et al. · Health Science Reports · 1
FDA approves IcotydeTM (Icotrokinra): a novel IL-23 receptor antagonist for plaque psoriasis
2026 · Muhammad Ali Abid, Muhammad Hafi Abid, et al. · Annals of Medicine and Surgery · 1
Contemporary Management of Thalassemia: A Perspective on Current Standards and the Emergence of FDA‐Approved Oral Therapy
2026 · Fnu Zainab, Abdul Haseeb Hasan, et al. · Health Science Reports
PDF
Bridging pathogenesis and therapy in focal segmental glomerulosclerosis: the rise of dual receptor blockade with sparsentan
2026 · Muhammad Ali Abid, Muhammad Hafi Abid, et al. · Annals of Medicine and Surgery
Temporal trends and disparities in gallbladder cancer mortality: A U.S. population-based study.
2026 · Muhammad Hassan, Masab Ali, et al. · Journal of Clinical Oncology
A paradigm shift in diabetes care: clinical implications of once-weekly insulin icodec
2026 · Muhammad Ali Abid, Muhammad Hafi Abid, et al. · Annals of Medicine and Surgery
Trends and disparities in hypertension and chronic liver disease-associated mortality in the United States: A retrospective population-based joinpoint regression analysis, 1999–2024
2026 · Naveed Ahmad, Syed Tawassul Hassan, et al. · JRSM Cardiovascular Disease
Yuvezzi™ (carbachol and brimonidine tartrate) dual-agent eyedrops: a new option for presbyopia
2026 · Muhammad Ali Abid, Muhammad Hafi Abid, et al. · Annals of Medicine and Surgery
Works count: 9
Citation count: 2
H-index: 1
I10-index:
Year
Topic
Type